Plasma Fractionation Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of Plasma Fractionation Market
The Plasma Fractionation market size was valued at USD 32.83 billion in 2023, and the market is now projected to grow from USD 35.21 billion in 2024 to USD 62.83 billion by 2032, exhibiting a CAGR of 7.5% during the forecast period of 2023-2030.
Strict hints applied at some stage in the pandemic led to a decline inside the plasma facilities' plasma quantity. Many key players running within the market located a decrease of their sales at some point of the pandemic.
Plasma-derived medicinal products are typically used to update poor proteins in an individual. Products derived from plasma aid in treating rare conditions affecting a fairly smaller proportion of the population. There is an exponential surge within the demand for plasma-derived treatment plans across the globe because of the rising burden of diverse immunodeficiency and uncommon genetic disorders. This outcomes in Plasma Fractionation market growth.
The plasma fractionation system involves breaking down plasma into various individual proteins, including albumin, immunoglobulin, coagulation factors, and protease inhibitors, for scientific use. The modern call for for plasma-derived healing procedures has brought about the release of diverse technologies which could make the technique faster.
Comprehensive Analysis of Plasma Fractionation Market
The Plasma Fractionation market is rising at an exponential charge due to its marketplace segmentation. Based on product, the market is categorized into immunoglobulin, inhibitors, coagulation factors, albumin, protease and others. Based on application, the market is segmented into pulmonology, critical care, immunology & hematology, neurology, and others. In terms of end-user, the market is categorized into clinical research laboratories, hospitals & clinics, and others.
North America has the largest Plasma Fractionation market share. The highest plasma fractionation market proportion of this location is attributed to numerous factors. Some elements include the presence of main groups developing and launching technologically superior plasma-derived treatment plans and merchandise, contributing definitely to the location’s increase.
The top players in the market play a crucial role in the Plasma Fractionation industry assuring industrial prospectus growth and setting market standards. These players include, Biotest AG (Germany), Grifols, S.A (Spain), Takeda Pharmaceutical Company Limited (Japan), CSL (U.S.), Kedrion S.p.A (Italy), Octapharma (Switzerland), CSL (U.S.), Bio Products Laboratory Ltd. (U.K.), and LFB (France).
In December 2023, Octapharma AG acquired extended approval from the U.S. FDA for its plasma-based product, wilate (von Willebrand Factor/Coagulation Factor VIII Complex).
Segmentation Table
Attribute Details
Study Period 2019-2032
Base Year 2023
Estimated Year 2024
Forecast Period 2024-2032
Historical Period 2019-2022
Growth Rate CAGR of 7.5% from 2024-2032
Unit Value (USD Billion)
Segmentation
By Product
Albumin
Immunoglobulin
- Intravenous Immunoglobulin
- Subcutaneous Immunoglobulin
Coagulation Factors
- Factor IX
- Factor VIII
- Prothrombin Complex Concentrates
- Fibrinogen Concentrates
- Others
Protease Inhibitors
Others
By Application
Immunology & Neurology
Hematology
Critical Care
Pulmonology
Others
By End-user
Hospitals & Clinics
Clinical Research Laboratories
Others
By Region
North America (By Product, Application, End-user, and Country)
- U.S. (By Product)
- Canada (By Product)
Europe (By Product, Application, End-user, and Country/Sub-Region)
- U.K. (By Product)
- Germany (By Product)
- France (By Product)
- Italy (By Product)
- Spain (By Product)
- Rest of Europe (By Product)
Asia Pacific (By Product, Application, End-user, and Country/Sub-Region)
- China (By Product)
- Japan (By Product)
- India (By Product)
- Australia (By Product)
- Southeast Asia (By Product)
- Rest of Asia Pacific (By Product)
Latin America (By Product, Application, End-user, and Country/Sub-Region)
- Brazil (By Product)
- Mexico (By Product)
- Rest of Latin America (By Product)
Middle East & Africa (By Product, Application, End-user, and Country/Sub-Region)
- GCC (By Product)
- South Africa (By Product)
- Rest of Middle East & Africa (By Product)
Please Note: It will take 2-3 business days to complete the report upon order confirmation.
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
- 4. Key Insights
- 4.1. Number of Plasma Collection Centers - by Key Countries/Sub-region
- 4.2. Plasma Fractionation Capacity - by Key Players
- 4.3. Cost Breakdown of Plasma Fractionation - by Country/Sub-region
- 4.4. Regional Distribution of Plasma Fractionation Throughput
- 4.5. Prevalence of Chronic Diseases (Key Indications) - by Key Countries/Sub-region, 2022/2023
- 4.6. Pipeline Analysis - by Key Companies
- 4.7. Overview: Plasma Collection Technologies
- 4.8. Regulatory Scenario by Key Countries
- 4.9. Key Industry Developments (Mergers, Acquisitions, and Partnerships)
- 4.10. Impact of COVID-19 on the Market
- 5. Global Plasma Fractionation Market Analysis, Insights and Forecast, 2019-2032
- 5.1. Market Analysis, Insights and Forecast – By Product
- 5.1.1. Albumin
- 5.1.2. Immunoglobulin
- 5.1.2.1. Intravenous Immunoglobulin
- 5.1.2.2. Subcutaneous Immunoglobulin
- 5.1.3. Coagulation Factors
- 5.1.3.1. Factor IX
- 5.1.3.2. Factor VIII
- 5.1.3.3. Prothrombin Complex Concentrates
- 5.1.3.4. Fibrinogen concentrates
- 5.1.3.5. Others
- 5.1.4. Protease Inhibitors
- 5.1.5. Others
- 5.2. Market Analysis, Insights and Forecast – By Application
- 5.2.1. Immunology & Neurology
- 5.2.2. Hematology
- 5.2.3. Critical Care
- 5.2.4. Pulmonology
- 5.2.5. Others
- 5.3. Market Analysis, Insights and Forecast – By End-User
- 5.3.1. Hospitals & Clinics
- 5.3.2. Clinical Research Laboratories
- 5.3.3. Others (Academic Institutes, etc.)
- 5.4. Market Analysis, Insights and Forecast – By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America
- 5.4.5. Middle East & Africa
- 6. North America Plasma Fractionation Market Analysis, Insights and Forecast, 2019-2032
- 6.1. Market Analysis, Insights and Forecast – By Product
- 6.1.1. Albumin
- 6.1.2. Immunoglobulin
- 6.1.2.1. Intravenous Immunoglobulin
- 6.1.2.2. Subcutaneous Immunoglobulin
- 6.1.3. Coagulation Factors
- 6.1.3.1. Factor IX
- 6.1.3.2. Factor VIII
- 6.1.3.3. Prothrombin Complex Concentrates
- 6.1.3.4. Fibrinogen concentrates
- 6.1.3.5. Others
- 6.1.4. Protease Inhibitors
- 6.1.5. Others
- 6.2. Market Analysis, Insights and Forecast – By Application
- 6.2.1. Immunology & Neurology
- 6.2.2. Hematology
- 6.2.3. Critical Care
- 6.2.4. Pulmonology
- 6.2.5. Others
- 6.3. Market Analysis, Insights and Forecast – By End-User
- 6.3.1. Hospitals & Clinics
- 6.3.2. Clinical Research Laboratories
- 6.3.3. Others (Academic Institutes, etc.)
- 6.4. Market Analysis, Insights and Forecast – By Country
- 6.4.1. U.S.
- 6.4.1.1. By Product
- 6.4.2. Canada
- 6.4.2.1. By Product
- 7. Europe Plasma Fractionation Market Analysis, Insights and Forecast, 2019-2032
- 7.1. Market Analysis, Insights and Forecast – By Product
- 7.1.1. Albumin
- 7.1.2. Immunoglobulin
- 7.1.2.1. Intravenous Immunoglobulin
- 7.1.2.2. Subcutaneous Immunoglobulin
- 7.1.3. Coagulation Factors
- 7.1.3.1. Factor IX
- 7.1.3.2. Factor VIII
- 7.1.3.3. Prothrombin Complex Concentrates
- 7.1.3.4. Fibrinogen concentrates
- 7.1.3.5. Others
- 7.1.4. Protease Inhibitors
- 7.1.5. Others
- 7.2. Market Analysis, Insights and Forecast – By Application
- 7.2.1. Immunology & Neurology
- 7.2.2. Hematology
- 7.2.3. Critical Care
- 7.2.4. Pulmonology
- 7.2.5. Others
- 7.3. Market Analysis, Insights and Forecast – By End-User
- 7.3.1. Hospitals & Clinics
- 7.3.2. Clinical Research Laboratories
- 7.3.3. Others (Academic Institutes, etc.)
- 7.4. Market Analysis, Insights and Forecast – By Country/ Sub-Region
- 7.4.1.
- 7.4.1.1. U.K.
- 7.4.1.1.1. By Product
- 7.4.1.2. Germany
- 7.4.1.2.1. By Product
- 7.4.1.3. France
- 7.4.1.3.1. By Product
- 7.4.1.4. Spain
- 7.4.1.4.1. By Product
- 7.4.1.5. Italy
- 7.4.1.5.1. By Product
- 7.4.1.6. Scandinavia
- 7.4.1.6.1. By Product
- 7.4.1.7. Rest of Europe
- 7.4.1.7.1. By Product
- 8. Asia Pacific Plasma Fractionation Market Analysis, Insights and Forecast, 2019-2032
- 8.1. Market Analysis, Insights and Forecast – By Product
- 8.1.1. Albumin
- 8.1.2. Immunoglobulin
- 8.1.2.1. Intravenous Immunoglobulin
- 8.1.2.2. Subcutaneous Immunoglobulin
- 8.1.3. Coagulation Factors
- 8.1.3.1. Factor IX
- 8.1.3.2. Factor VIII
- 8.1.3.3. Prothrombin Complex Concentrates
- 8.1.3.4. Fibrinogen concentrates
- 8.1.3.5. Others
- 8.1.4. Protease Inhibitors
- 8.1.5. Others
- 8.2. Market Analysis, Insights and Forecast – By Application
- 8.2.1. Immunology & Neurology
- 8.2.2. Hematology
- 8.2.3. Critical Care
- 8.2.4. Pulmonology
- 8.2.5. Others
- 8.3. Market Analysis, Insights and Forecast – By End-User
- 8.3.1. Hospitals & Clinics
- 8.3.2. Clinical Research Laboratories
- 8.3.3. Others (Academic Institutes, etc.)
- 8.4. Market Analysis, Insights and Forecast – By Country/ Sub-Region
- 8.4.1. Japan
- 8.4.1.1. By Product
- 8.4.2. China
- 8.4.2.1. By Product
- 8.4.3. India
- 8.4.3.1. By Product
- 8.4.4. Australia
- 8.4.4.1. By Product
- 8.4.5. Southeast Asia
- 8.4.5.1. By Product
- 8.4.6. Rest of Asia Pacific
- 8.4.6.1. By Product
- 9. Latin America Plasma Fractionation Market Analysis, Insights and Forecast, 2019-2032
- 9.1. Market Analysis, Insights and Forecast – By Product
- 9.1.1. Albumin
- 9.1.2. Immunoglobulin
- 9.1.2.1. Intravenous Immunoglobulin
- 9.1.2.2. Subcutaneous Immunoglobulin
- 9.1.3. Coagulation Factors
- 9.1.3.1. Factor IX
- 9.1.3.2. Factor VIII
- 9.1.3.3. Prothrombin Complex Concentrates
- 9.1.3.4. Fibrinogen concentrates
- 9.1.3.5. Others
- 9.1.4. Protease Inhibitors
- 9.1.5. Others
- 9.2. Market Analysis, Insights and Forecast – By Application
- 9.2.1. Immunology & Neurology
- 9.2.2. Hematology
- 9.2.3. Critical Care
- 9.2.4. Pulmonology
- 9.2.5. Others
- 9.3. Market Analysis, Insights and Forecast – By End-User
- 9.3.1. Hospitals & Clinics
- 9.3.2. Clinical Research Laboratories
- 9.3.3. Others (Academic Institutes, etc.)
- 9.4. Market Analysis, Insights and Forecast – By Country/ Sub-Region
- 9.4.1. Brazil
- 9.4.1.1. By Product
- 9.4.2. Mexico
- 9.4.2.1. By Product
- 9.4.3. Rest of Latin America
- 9.4.3.1. By Product
- 10. Middle East & Africa Plasma Fractionation Market Analysis, Insights and Forecast, 2019-2032
- 10.1. Market Analysis, Insights and Forecast – By Product
- 10.1.1. Albumin
- 10.1.2. Immunoglobulin
- 10.1.2.1. Intravenous Immunoglobulin
- 10.1.2.2. Subcutaneous Immunoglobulin
- 10.1.3. Coagulation Factors
- 10.1.3.1. Factor IX
- 10.1.3.2. Factor VIII
- 10.1.3.3. Prothrombin Complex Concentrates
- 10.1.3.4. Fibrinogen concentrates
- 10.1.3.5. Others
- 10.1.4. Protease Inhibitors
- 10.1.5. Others
- 10.2. Market Analysis, Insights and Forecast – By Application
- 10.2.1. Immunology & Neurology
- 10.2.2. Hematology
- 10.2.3. Critical Care
- 10.2.4. Pulmonology
- 10.2.5. Others
- 10.3. Market Analysis, Insights and Forecast – By End-User
- 10.3.1. Hospitals & Clinics
- 10.3.2. Clinical Research Laboratories
- 10.3.3. Others (Academic Institutes, etc.)
- 10.4. Market Analysis, Insights and Forecast – By Country/ Sub-Region
- 10.4.1. GCC Countries
- 10.4.1.1. By Product
- 10.4.2. South Africa
- 10.4.2.1. By Product
- 10.4.3. Rest of Middle East & Africa
- 10.4.3.1. By Product
- 11. Competitive Analysis
- 11.1. Global Market Share Analysis (2023)
- 11.2. Company Profiles
- 11.2.1. CSL
- 11.2.1.1. Overview
- 11.2.1.2. Products & Services
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Baxter
- 11.2.2.1. Overview
- 11.2.2.2. Products & Services
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. Kedrion S.p.A.
- 11.2.3.1. Overview
- 11.2.3.2. Products & Services
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. Octapharma
- 11.2.4.1. Overview
- 11.2.4.2. Products & Services
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. Grifols, S.A.
- 11.2.5.1. Overview
- 11.2.5.2. Products & Services
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. Biotest AG
- 11.2.6.1. Overview
- 11.2.6.2. Products & Services
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based on Availability)
- 11.2.7. Shire
- 11.2.7.1. Overview
- 11.2.7.2. Products & Services
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. LFB
- 11.2.8.1. Overview
- 11.2.8.2. Products & Services
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based on Availability)
- 11.2.9. Other prominent players
- 12. Strategic Recommendations
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook